Clinical Trial

A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-20.
Trial Details
NCT Number NCT07723976
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Research UK Limited
Conditions Developmental and Epileptic Encephalopathy (DEE)
Enrollment 120 participants
Start Date 2026-10-30
Primary Completion 2029-09-04 (estimated)
Study Completion 2029-09-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-24